Eli Lilly and Co’s Evista osteoporosis drug works as well as the older tamoxifen in reducing the risk of breast cancer in high-risk women, with fewer dangerous side effects, researchers said on Monday.

The results of the 19,000-woman Study of Tamoxifen and Raloxifene (STAR) trial show that Evista, known generically as raloxifene, is less likely than tamoxifen to cause blood clots and uterine cancer.

Full Story: Reuters.